

# Demystifying the Obesity Paradox in Acute Conditions and Injuries

**Bowei Su\* and Sebastien Fuchs**

*Western University of Health Sciences, USA*

---

**\*Corresponding author:** Bowei Su, Western University of Health Sciences, USA,  
Tel: 4083682478; E-mail: [bowei.su@westernu.edu](mailto:bowei.su@westernu.edu)

**Received** January 12, 2021; **Accepted** February 15, 2021; **Published** February 22, 2021

**Citation:**

in oBMI a i a ion a o H a  
O aniza ion an Na iona In i o H a (Ta 1).

## Results

### Clinical presentations

#### Trauma

O ini ia in i a ion an i an in i o o i  
o x a in in o n a .S i on  
a ion i n n a o ai an o i a n  
a in in on i n n in . R o i o o i 7,8  
no ini an i n in n a o ai a o a  
BMI o .A iona in a in n i a o , o i a an  
IC n o (LOS) a o ani a in a in BMI a o  
LOS i o i o a in o a o no i  
a in . D o a a ., 9 in a o n a - a a ion i



ino, Sanza, 29 o a ai n i  
o i in a o i o o an no a in ia io a  
ani in i a a ox, i o .

**Critical care/sepsis/lung injury**

O i a a ox a n i a n an in in o  
i a a an in ni a ni (IC) ain .A 2008 a-ana i  
A in i a., 24 xa in o i on IC o ai  
ani a nia ion a, an IC n o a in 14 i (7  
o i, 7 o i). on no ini an i n in  
IC o ai a a o a i o i i ia  
in o o a o non-o o i o ia i a 24 .  
a o on a ion o a nia nia ion (1.48 a)  
an IC a (1.08 a) i o ain o a o non-o .  
S n o ana i a no i n in IC o ai  
n non-o an o i o ain ; o ain i  
BMI 30-39.9 /<sup>2</sup> a a o o ai a o a o non-o  
30 . In a a - a o a ion a o o D IC ain i  
BMI n ai o o a ion, Pi a., 26 on an  
in J- a a ion i n BMI an in- o ia o ai  
a , i ini a i a BMI 42.6 /<sup>2</sup> (o i o , C a III)  
an in a in x on nia a BMI o 20 /<sup>2</sup> (no a non-  
o ) .

In o i a i ion, P o a., 31 a a l- a  
o ai n i o ain in o i o o . i  
a a ox i i in- o ia an 90- a o ai a , an  
i a o a i a ion n ain n an o 70 a  
o . i o a ion a o a o o i  
o o i 32,33 . Ho , n on o i  
o a o i n a j n o o- o i i an  
in n ion a 34,35 .

Li a on a n inj in a 2016 a-ana i  
i a., 25 xa in in o i a a ox in a ia o  
i n o (ARDS), i o i 25 i (9 o i ,  
16 o i ) . a o o n a ini an o a ion n  
in a BMI, o i an o ARDS/a n inj o ai  
a ion i a o in o - a , i o ain  
(BMI 30-39.9 /<sup>2</sup>) a o o ai a an no a o ia ion  
n o i o i an ARDS o ai In o ana i o  
i i a a ia a a, a o i no n an a ion i  
no i an 28 a o ai o , o i a a o ia  
i o 60 an 90- a o ai

**COVID-19**

In i o in No Co ona i Di a 2019  
(CO ID-19) an i a i o i in , i  
i a o o i on CO ID-19 o no i . A on in  
a a i a a-ana i on H ain a., 36 x o in  
a o ia ion n CO ID-19 o ai an a i a o  
in in a , x, BMI, an n o o i i an  
i i a in . i in 6 a a in o o a BMI a a, a o  
o n a ini an o i i a o ia ion i o i an o ai i  
ano i o BMI o 25 /

L in i o n i a a i o i a n i n a n  
o n a o i a i n a i i o i a a n a i a i n i o n a  
a o - i n a a o i i 9,30,40,42 .

A i o n i n i a n i - a o n i a i o i n i o n o  
i o i n i n n i i i a n a o o i i i  
o n o a i o a a i a a n a o i  
a n i n i n i n o 43 .

P o - i n a a o C o i n I n a o I L - 6 , I L -  
8 , S a P o i n - D ( S P - D ) , o n i a n F a o ( F ) , a n  
P a j i n o n a i a o I n i i o - 1 ( P A I - 1 ) a n a o i a i  
i n a o o a 44 . O a i n i n o  
o i i i o o - i n a a o o i n  
i n a a ; o , a i n  
o o i n a n a o a n i a n i n a o a n i - i n a a o  
o i n ( i . I L - 10 ) . I n i n i a n o n i n n o n -  
o a i n 6 . I n i n o a n i n j S a o n a . ,  
44 a o o n a i n a i n B M I a a o i a i o  
i n a a o o i n , i a I L - 6 , I L - 8 , a n S P - D . i a o  
n a n i n a i n F ( i o a o n o i a a a ) a o n  
o a i n , a n i o x i n o a o i n a o  
o i a a o i o n o a n i n i a a i o n i .  
a a a i n a . , 32 o n a i j a a i n I L - 6 o i o n  
a n a o a o n a n n a i n i o n a o n o i a n  
o a i n , a i n o o 28 - a a i i i .

T i N o i F a o - A a ( T N F - ) A i o i o n o  
o T N F - o a n i o o o n a a  
o - i n a a o o T N F - i n i a n o - o a i n  
19,40 .

**Anti-oncogenic properties**

a a i o i

ia o a a Man o i a-ana on  
nn o i a ana ,an A inn i a., 30 i n an n -  
i a ion o n ai . Ho , a-ana a o  
a i o o a a i a a a ion i B , an o a ion  
an no ia 5,12,24,25 .

o i i i o o a i a ia a a o o o ,a o o  
in i o i ina o ,No A , i an an E o an  
i , i in a ion on Ca a ian o a ion 5,49 . i in  
o ana i, a., 24 on a i i a o o o a  
an i a i o i an o i on a i o non-  
No A , i an ion . A ain, na o i a ion i  
i o n o o no BMI a a o ion,  
a a , an na on on on a o a a  
o . In a ion o o a i a ia , na j a ia  
in o - a i a i n a a o i a i a o  
a on i o a i i n n o an non-  
o . i i i o an o a o in in i a ion o  
no non.

Ano a o o on i a ion i no ion o a n ia ,  
o a in a in n i in i a i a  
an i i an in a in i a i i o a ion. O  
a., 19 i a in ni an i o a a ion, ain, an  
an i ni a n o - o i o ain a  
a o in a i a an n iona n oin . S a  
i a a i a n o , i a  
o i on i n i o o i a ion, i . a  
in a ion in a i a ion o i ai an o in o  
o IC a i ion . P o a., 31 on i i a o i n  
o o a i ion i n in o in ain  
o a ion a o in o ia no i an no IC a i ion, an  
i a on ion in a n i o i a a ox. n  
n o a o in ia a i o a a a  
i i z a ion ia , in i a a n in an o  
i i z a ion o a n n a o i a ion n o i  
an a a i n . on a o ain in  
i ni an o o in a o o in i a o  
i i i a a . Ho , a a a i a a o n an  
a o a i in n iona i i a ion a i a n o non-o  
ain . On i n i o i i i o o ain  
ia no i i n in o , an n - a n ia . F i  
o - i a ion a n n o i , n a in a i ain  
an i in i i a i o onon-o ain a o n o  
a i i a o o a o o o i - a o in . Si i a  
n in o in o an x i a o in  
o a o o an an i o i 40 . F in i a ion in  
a n ia o o i a a o o a  
i a i in n on o i an a i

**BMI metric/Documentation**

A i ion o a i i o BMI i in x o o i  
a a ox. BMI i a a i in i o a o a  
o i in ( / ) an i a a o a o o  
n iona a . I a i a o i an a iz  
n ion o i a o i an in n i i i i in  
o a an (LM) an a (FM) i n i a ion 9,40 . BMI a  
a i i o 96% an n i i i o 43% in o i a n in  
o a ion o o a na a n 19 . i an a.,  
50 on a a o a o o i in i i a an 31.7%

( / i/ o a n) o o a o axi iz  
n o a n an i a o i  
a o o i in an a a i n .A iona i o  
i o an o i a i n i an o POP a a  
on o n in a o i in o i a a ox. I i a a  
o i i i n a o o a a , an o o a in  
o a ion, o a ion a i i i o an  
o a o o i in o o no i o i i a o o i .T  
o i i a o i a no n a i a jo a i a o  
n ain in i o i a in in in i a ion  
a a a i n i an i i a ion in i in a i  
ana n .

**References**

- 1.

42. Maurya R, Bhattacharya P, Dey R, Nakhasi HL (2018) Leptin functions in infectious diseases. *Frontiers in Immunology* 9: 2741-2741.
43. Barth RF, Buja LM, Cao L, Brodsky SV (2017) An obesity paradox: Increased body mass index is associated with decreased aortic atherosclerosis. *Curr Hypertens Rep* 19: 55.
44. Stapleton RD, Dixon AE, Parsons PE, Ware LB, Suratt BT, et al. (2010) The association between BMI and plasma cytokine levels in patients with acute lung injury. *Chest* 138: 568-577.
45. Lee YM, Kim KS, Jacobs DR Jr, Lee DH (2017) Persistent organic pollutants in adipose tissue should be considered in obesity research. *Obesity Reviews* 18: 129-139.
46. Merrill ML, Emond C, Kim MJ, Jean-Philippe A, Le Bizec B, et al. (2013) Toxicological function of adipose tissue: Focus on persistent organic pollutants. *Environmental Health Perspectives* 121: 162-169.
47. Kim MJ, Marchand P, Henegar C, Jean-Philippe A, Alili R, et al. (2011) Fate and complex pathogenic effects of dioxins and polychlorinated biphenyls in obese subjects before and after drastic weight loss. *Environ Health Perspect* 119: 377-383.
48. Hong NS, Kim KS, Lee IK, Lind PM, Lind L, et al. (2012) The association between obesity and mortality in the elderly differs by serum concentrations of persistent organic pollutants: A possible explanation for the obesity paradox. *International Journal of Obesity* 36: 1170-1175.
49. Borgeraas H, Hertel JK, Tveitevåg Svingen GF, Seifert R, Pedersen EKR, et al. (2014) Association of body mass index with risk of acute myocardial infarction and mortality in Norwegian male and female patients with suspected stable angina pectoris: A prospective cohort study. *BMC Cardiovascular Disorders* 14: 68-68.
50. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, et al. (2008) The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: Prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). *Arch Intern Med* 168: 1617-1624.
51. Carbone S, Canada JM, Billingsley HE, Siddiqui MS, Elagizi A, et al. (2019) Obesity paradox in cardiovascular disease: where do we stand? *Vascular Health and Risk management* 15: 89-100.